Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.1.49 CHF
Change Today -0.02 / -1.32%
Volume 1.6M
As of 11:43 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

evolva holding sa (EVE) Snapshot

Open
SFr.1.51
Previous Close
SFr.1.51
Day High
SFr.1.51
Day Low
SFr.1.45
52 Week High
05/28/15 - SFr.1.86
52 Week Low
10/10/14 - SFr.1.07
Market Cap
488.1M
Average Volume 10 Days
1.5M
EPS TTM
SFr.-0.09
Shares Outstanding
327.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOLVA HOLDING SA (EVE)

Related News

No related news articles were found.

evolva holding sa (EVE) Related Businessweek News

No Related Businessweek News Found

evolva holding sa (EVE) Details

Evolva Holding SA, a biosynthetic company, discovers, develops, manufactures, and commercializes ingredients for nutrition, health care, and wellness products in Switzerland and internationally. The company’s principal products include Resveratrol, a natural compound produced in grapes and other plants as a response against environmental stress factors; Vanillin, a complex blend of compounds extracted from the seed pods of the vanilla orchid; and Stevia, a natural, zero-calorie food, and beverage sweetener derived from Stevia rebaudiana, a leafy green plant for family. It also offers Nootkatone, a citrus ingredient associated with grapefruits, which is used as a flavor and fragrance ingredient; and as agent against a range of insect pests, including ticks, bed bugs, and mosquitoes. In addition, the company provides Agarwood for perfume makers and traditional medicine practitioners; Saffron, a spice made by yeast fermentation; Valencene, an orange flavor and fragrance ingredient used in food and drink, personal care, and household products, as well as an intermediate to produce nootkatone; and Sandalwood, an oil used in preparing various types of perfume compositions. Further, it offers legacy products, such as EV-077, a compound for diabetic nephropathy and other diabetic complications; EV-35, a preclinical antibiotic; and Pomecins, an antifungal ingredient that prevent mould and yeast growth. The company is based in Reinach, Switzerland.

144 Employees
Last Reported Date: 03/31/15

evolva holding sa (EVE) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: SFr.388.7K
Compensation as of Fiscal Year 2014.

evolva holding sa (EVE) Key Developments

Evolva Holding Sa. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Evolva Holding SA. reported consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenue was CHF 8.3 million against CHF 5.0 million a year ago. Net loss was CHF 17.0 million against CHF 10.6 million a year ago. Loss per share was CHF 0.05 against CHF 0.04 per share a year ago. Total R&D expenses increased by 56% to CHF 18.1 million from CHF 11.6 million in 2014. This reflects a 41% increase in R&D headcount (from 79 to 111) as a result of the Allylix acquisition and new hires over the last 12 months, not least in scale-up and application development. The operating cash outflow rose to CHF 14.8 million in 2015 from CHF 9.4 million in 2014. Of the total increase, CHF 3.7 million relates to settlement of the remaining liabilities assumed from Allylix in December 2014. The company expects revenues to be around CHF 14 million in 2015 subject to achievement of certain milestones and the development of product sales before year-end. Product sales are expected to make a meaningful revenue contribution but the majority of revenues will still derive from R&D partnerships. The operating cash outflow in the second half of 2015 is expected to increase compared with the first half, not least due to an increase in costs to manufacturing and sales and marketing.

Evolva Launches Nootkatone, Highly Prized Citrus Flavour and Fragrance Ingredient

Evolva announced the launch of nootkatone, a highly prized citrus flavour and fragrance (F&F) ingredient. By brewing nootkatone from sugar, rather than extracting it from the skin of grapefruits, Evolva's process allows nootkatone to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has now begun selling nootkatone as a F&F ingredient to food, beverage, personal care, and home care product producers around the world. Nootkatone is a natural aroma ingredient that occurs in grapefruit and certain other plants. Nootkatone is a natural aroma ingredient that occurs in grapefruit and certain other plants. It is responsible for the characteristic smell of grapefruit. With a record of demonstrated safety, it is approved in all major countries for use in F&F, and is used in a wide range of foods, drinks, and skin care products. However, until now, its use has been limited by its high price, limited supply, product quality, and other factors. But nootkatone's commercial prospects go significantly beyond F&F. In both laboratory and field studies, nootkatone has demonstrated excellent activity against biting and nuisance pests, notably the ticks that are responsible for spreading Lyme disease, but also mosquitoes, head lice, bed bugs and other pests. Earlier this year Evolva therefore submitted a request to the US Environmental Protection Agency (EPA) to classify nootkatone as a biochemical pesticide active ingredient (a subcategory of biopesticide). Such a classification allows for a potentially expedited process for registration of nootkatone for use against pests. Evolva received approval of this request on August 19, 2015, and will now engage in an estimated 2-3 years of regulatory work to get nootkatone approved as an insect and tick repellent in the USA. Evolva is also investigating other geographies.

Evolva Holding SA., H1 2015 Earnings Call, Aug 26, 2015

Evolva Holding SA., H1 2015 Earnings Call, Aug 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVE:SW SFr.1.49 CHF -0.02

EVE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GLG Life Tech Corp C$0.34 CAD 0.00
Ingredion Inc $86.64 USD +0.54
PureCircle Ltd 400.00 GBp 0.00
Stevia First Corp $0.16 USD +0.03
View Industry Companies
 

Industry Analysis

EVE

Industry Average

Valuation EVE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.4x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOLVA HOLDING SA, please visit www.evolva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.